Table 3 Clinical outcomes stratified by AKI severity in pediatric cohort
|  | Stage 1 (n = 17) | Stage 2 (n = 13) | Stage 3 (n = 11) | non-AKI (n = 113) | p-value |
|---|---|---|---|---|---|
DGF, n (%) | 6 (35.3) | 3 (23.1) | 5 (45.5) | 19 (16.8) | 0.039 |
AR, n (%) | 2 (11.8) | 1 (7.7) | 4 (36.4) | 16 (14.2) | 0.461 |
SCr, µmol/L, median (IQR) |  |  |  |  | |
 1 week | 411.34 (200.83–621.87) | 287.53 (88.55–486.50) | 310.13 (159.70 (460.55) | 299.16 (239.00–359.32) | 0.299 |
 1 month | 117.45 (93.47–141.43) | 106.74 (90.95–122.53) | 112.45 (87.24–137.66) | 126.15 (108.53–143.78) | 0.988 |
 6 months | 157.66 (81.65–233.67) | 80.25 (59.56–100.94) | 105.65 (77.86–133.44) | 95.62 (87.35–103.88) | 0.026 |
 12 months | 118.98 (78.21–59.74) | 83.64 (71.69–95.59) | 110.96 (64.77–157.16) | 91.63 (83.37–99.91) | 0.129 |
1-year clinical outcome | Â | Â | Â | Â | Â |
 Graft loss incident, n (%) | 1 (5.9) | 0 (0) | 0 (0) | 1 (0.9) | 0.228 |
 Death-censored graft survival rate, (%) | 94.1 | 100 | 100 | 99.1 | 0.402 |
 Patient death incident, n (%) | 0 (0) | 0 (0) | 0 (0) | 3 (2.7) | 0.392 |
 Patient survival, (%) | 100 | 100 | 100 | 97.3 | 0.777 |